Andrew Östör
8PUBLICATIONS
22CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Mar 19, 2026
Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study.Andrew Östör, Eugen Feist, Prodromos Sidiropoulos
|Oct 01, 2025
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials.Andrew Östör, Filip Van den Bosch, Kim Papp
|Mar 04, 2025
Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease.Victoria Navarro-Compán, Filip Van den Bosch, Percival Degrava Sampaio-Barros
|Mar 18, 2024
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.Andrew Östör, Filip Van den Bosch, Kim Papp
|Oct 25, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.Andrew Östör, Filip Van den Bosch, Kim Papp
|Jul 27, 2022
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension.Désirée van der Heijde, Atul Deodhar, Walter P Maksymowych
Pageof 2
Frequent Collaborators
2 joint publications
Alan Kivitz
2 joint publications
Ricardo Blanco
2 joint publications
Kim Papp
1 joint publications
Lila Glotfelty
1 joint publications
Philip J Mease
1 joint publications
Xenofon Baraliakos
1 joint publications
Victoria Navarro-Compán
1 joint publications
Percival Degrava Sampaio-Barros
1 joint publications
Sofia Ramiro
1 joint publications
Walter P Maksymowych
